GlassScriptPhysician profile
Rochelle Feldman
NPI 1053368167
$4,796.98
in general payments reported to CMS, 2019-2025
24 companies · $1,342 in 2025
The $1,342 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $531 · 2021: $748 · 2022: $321 · 2023: $421 · 2024: $1,195 · 2025: $1,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,949 · Education: $9.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,948.96 |
| Education | $9.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,471.98 | 2021-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $736.92 | 2020-2022 | |
| Acadia Pharmaceuticals INC | $473.19 | 2025 | Daybue |
| Pfizer INC. | $304.18 | 2020-2024 | |
| Travere Therapeutics, INC. | $302.34 | 2019-2023 | Cholbam |
| Merck Sharp & Dohme LLC | $224.87 | 2020-2025 | Gardasil 9, Vaxneuvance, M-M-R II |
| Advanced Respiratory, INC | $184.72 | 2019-2021 | |
| Sanofi Pasteur INC. | $138.82 | 2019-2025 | |
| Csl Behring | $124.99 | 2024 | Hizentra |
| Octapharma USA, INC. | $114.67 | 2022-2023 | Panzyga, Octagam Immune Globulin (Human) |
| Tris Pharma INC | $113.11 | 2021-2025 | Dyanavel Xr, Onyda Xr |
| Cranial Technologies, INC | $86.87 | 2022-2025 | Doc Band |
| Abbott Laboratories | $71.01 | 2023-2025 | Id Now Instrument |
| Corium, LLC | $70.37 | 2025 | Azstarys |
| Mirum Pharmaceuticals, INC. | $66.82 | 2024 | Livmarli, Cholbam |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $55.99 | 2022-2023 | |
| Alk-Abello, INC | $41.72 | 2023-2024 | Grastek, Ragwitek, Odactra |
| Electromed, INC. | $41.00 | 2021-2022 | |
| Boston Scientific Corporation | $32.51 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $31.98 | 2024 | Bylvay |
| Phadia US INC. | $31.95 | 2023-2024 | Immunocap |
| Shire North American Group INC | $31.76 | 2019 | |
| Lnhc, INC | $24.97 | 2025 | Zelsuvmi |
| Glaxosmithkline, LLC. | $20.24 | 2023 | Rotarix, Pediarix, Bexsero |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rochelle Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.